ACNE VULGARIS · White paper
Acne Vulgaris Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About acne vulgaris — and why its trials are hard
Acne vulgaris is a chronic inflammatory disease of the pilosebaceous unit driven by excess sebum, follicular hyperkeratinization, Cutibacterium acnes colonization, and inflammation. It affects up to 85% of adolescents and 15-20% of adults, persisting most often in adult women. Trials are difficult because efficacy hinges on lesion counting and Investigator's Global Assessment (IGA) scores that are subjective and vary between clinicians and sites, inflating measurement noise. Placebo (vehicle) response rates are high, since vehicles themselves can improve mild-to-moderate acne, shrinking the treatment-versus-control gap. Adherence to topical regimens is frequently below 50% due to irritation and inconvenience, and darker skin types are under-represented, leaving post-inflammatory hyperpigmentation outcomes poorly characterized. Long-term follow-up needed to judge remission and recurrence suffers high attrition, and antibiotic arms must monitor resistance. Standardized grading scales, blinded central readers, digital imaging, adequate powering for dropout, and stratified enrollment across skin phototypes are the main levers for reliable, FDA-acceptable acne trial data.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| isotretinoin (Accutane) | 1982 | severe recalcitrant nodulocystic acne | pivotal nodular acne studies (label) | reduction in nodular/cystic lesion count and sebum suppression | long-term remission after a single course; often durable clearance (label; NCT00051497 reported ~70% remission at 6 months, unverified) |
| tretinoin (topical retinoid) (Retin-A) | 1971 | mild-to-moderate comedonal/inflammatory acne | vehicle-controlled topical studies | reduction in comedones and inflammatory lesions | significant lesion reduction and prevention of new comedones vs vehicle (magnitude varies by study, unverified) |
| dapsone (Aczone gel 5%) | 2005 | 12+ years, mild-to-moderate inflammatory acne | two vehicle-controlled Phase 3 studies | treatment success on Global Acne Assessment (0-4) and % lesion reduction at 12 weeks | treatment success 42% vs 32% (vehicle) in Study 1; inflammatory lesion reduction 46% vs 42% |
| trifarotene (Aklief) | 2019 | 9+ years, facial and truncal acne | PERFECT 1 and PERFECT 2 | IGA/PGA success and absolute lesion reduction at week 12 | significantly higher IGA success vs vehicle on both face and trunk (exact rates unverified) |
| sarecycline (Seysara) | 2018 | 9+ years, moderate-to-severe inflammatory acne (narrow-spectrum oral tetracycline) | SC1401 and SC1402 | IGA success and inflammatory lesion count reduction at week 12 | significant inflammatory lesion reduction vs placebo with lower systemic antibiotic exposure (exact rates unverified) |
| clascoterone (Winlevi) | 2020 | 12+ years, moderate-to-severe acne (first-in-class topical androgen receptor inhibitor) | CB-03-01/25 and /26 (Phase 3) | IGA success (2-grade improvement + clear/almost clear) at week 12 | significantly higher IGA success vs vehicle in both trials (exact rates unverified) |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in acne vulgaris development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| SB204 (nitric oxide-releasing gel) — NCT02322086 (NI-AC301/NI-AC302, Novan) | failed to meet co-primary efficacy endpoints in Phase 3 | inconsistent efficacy across the two pivotal trials for a novel nitric-oxide mechanism; underscored need for robust mechanism-based dose-finding before Phase 3 |
| olumacostat glasaretil (DRM01, Dermira) — CLAREOS-1/CLAREOS-2 (Phase 2b/3) | did not meet primary efficacy endpoints; development discontinued | topical sebum-inhibitor (acetyl-CoA carboxylase) could not separate from vehicle, reflecting the high vehicle response that plagues topical acne trials (unverified) |
| botulinum toxin A (intradermal, NDA-001) — NCT02519526 (Phase 2) | halted after interim data showed insufficient sebum-production reduction | single-target sebum modulation did not translate into meaningful lesion-count reduction, favoring multimodal approaches |
Choosing the right endpoint
Primary endpoints that matter in acne vulgaris trials
- Inflammatory and non-inflammatory lesion counts — Objective and FDA-preferred, but manual counting is subjective and varies across raters/sites; standardized grading and central/digital reading improve reliability.
- Investigator's Global Assessment (IGA) success — Co-primary with lesion counts (2-grade improvement to clear/almost clear); simple but coarse and susceptible to inter-rater drift without training.
- Vehicle (placebo) response control — Vehicles alone improve mild-to-moderate acne, so trials must be powered for a large placebo effect and may use run-in phases to identify high responders.
- Quality-of-life (DLQI) — Captures psychosocial burden central to acne, but self-report is subjective; validated instruments and interviews reduce noise.
- C. acnes load / antibiotic resistance — Relevant for antimicrobial agents; qPCR quantification and resistance monitoring guard against declining efficacy over time.
How iNGENū runs acne vulgaris trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
The full white paper: approved-product analyses, pivotal endpoints and trial-design strategy. Open-access · no sign-in.
Frequently asked questions
Acne Vulgaris clinical trials — FAQs
Why do so many acne trials fail despite an effective-looking drug?
What are the FDA co-primary endpoints for acne trials?
Were clascoterone and trifarotene really failures?
Ready to discuss your acne vulgaris trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal